AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

One very positive piece of news from the AZN-Oxford study is that the doses may be refrigerated at normal cooler temperatures.

AstraZeneca-Oxford Vaccine at 70% Efficacy

AstraZeneca will sell its vaccine to governments at significantly lower prices as compared to Pfizer and Moderna.

AstraZeneca confuses investors after reporting two different efficacy rates achieved by its Covid-19 vaccine

AstraZeneca plc (NASDAQ: AZN) announced Monday interim Phase 3 data for its coronavirus vaccine candidate AZD1222 from studies conducted in the U.K. and Brazil, showing efficacy ranging between 62% and 90%. The AstraZeneca Analysts: SVB Leerink analyst Geoffrey Porges has an Outperform rating on AstraZeneca with a $65 price target.

AstraZeneca Analyst Flags Lack Of Details In Interim COVID-19 Vaccine Data

AstraZeneca's experimental COVID-19 vaccine is the third vaccine to demonstrate it can prevent coronavirus infections in a late-stage clinical trial, though the viral vector-based vaccine is much less efficacious than the other leading vaccine candidates.

AstraZeneca's COVID-19 vaccine data fails to impress Wall Street analysts with its effectiveness in clinical trials

BioNTech SE

Gilead Sciences

Eli Lilly

Moderna

Pfizer

Regeneron Pharmaceuticals

A COVID-19 vaccine appears to be just around the corner, and many of the companies developing drugs, cocktails, vaccines and treatments are very close to crossing the finish line.

With a Vaccine Coming Soon, Where Do These COVID-19 Stocks Stand?

Late-stage trials early data reveals the vaccine, which will cost a few dollars, is up to 90% effective and can be stored at normal refrigerated conditions.

AstraZeneca, Oxford Say Cheap, Easy to Store Vaccine Is Up to 90% Effective

Analysts at Jefferies said that when it comes to storage, affordability, and distribution, AstraZeneca's vaccine appears to have an advantage.

AstraZeneca's Covid vaccine might seem less effective than its peers — but it has some advantages

For the third time this month, a potential vaccine for the global scourge shows extremely strong results.

AstraZeneca Coronavirus Vaccine Candidate Shows Up to 90% Efficacy in Interim Analysis

U.K.-based drugmaker AstraZeneca said on Monday that the coronavirus vaccine it is developing with the University of Oxford had shown an average efficacy of 70% in the Phase 3 trials.

What to expect after the Oxford-AstraZeneca COVID-19 vaccine news

Hello, Another Monday, another batch of vaccine results. This time: AstraZeneca and the University of Oxford shared that their coronavirus vaccine was 70% effective on average. That comes on the heels of Pfizer and its partner BioNTech and Moderna both sharing last week that their coronavirus vaccines were 95% and 94.5% effective, respectively. 

A 3rd coronavirus vaccine works

An interim analysis of the COVID-19 vaccine in development by Oxford University and biotech firm AstraZeneca has shown encouraging results, with data from the large, phase 3 clinical trial demonstrating an average "effectiveness" of 70.4%, according to the vaccine development team.

Oxford coronavirus vaccine is 70% effective on average, researchers say

Oxford University's COVID-19 vaccine, being developed in partnership with drugmaker AstraZeneca, has shown to be 70.4% effective in preliminary results from its Phase 3 clinical trial. That rate actually includes data from two different approaches to dosing, including one where two full strength does were applied, which was 62% effective, and a much more promising […]

Oxford University's COVID-19 vaccine shows high efficacy, and is cheaper to make and easier to store

The effacacy of the Oxford vaccine is relatively low compared to Moderna's and Pfizers–but it has two major advantages over its competitors, too. Another week and more good news in the fight against COVID-19.

Oxford COVID-19 vaccine: not as effective, but better than other vaccines in two big ways

In an announcement on Monday, AstraZeneca plc (LON: AZN) said that interim results from its late-stage clinical trials suggest that its candidate COVID-19 vaccine is effective in 70% of the patients on average. The news came only weeks after Pfizer/BioNTech and Moderna reported nearly 95% efficacy for their respective Coronavirus vaccines, as per the preliminary results.

AstraZeneca says its COVID-19 vaccine has an efficacy of 70% on average

Oxford Biomedica notes AstraZeneca's AZD1222 met primary efficacy endpoint in preventing COVID-19

The COVID-19 vaccine developed by the University of Oxford and AstraZeneca — which they say is 70% effective — overcomes some of the challenges associated with the rollout of Pfizer and Moderna's vaccines, making it cheaper, and potentially easier, to distribute globally, the manufacturers say. Unlike Pfizer and BioNTech's candidate, Oxford and AstraZeneca's vaccine doesn't have to be stored and transported at ultra-low temperatures. This could be especially beneficial for developing nations.

Oxford and AstraZeneca's COVID-19 vaccine is considerably cheaper and easier to distribute than either Pfizer's or Moderna's. Here's why.

The vaccine is cheaper and much easier to transport than Pfizer and Moderna's vaccines, which are 95% effective.

AstraZeneca-Oxford Vaccine Up To 90% Effective At Preventing Covid-19, Early Results Show

AstraZeneca shares fell 2% on Monday after announcing its Oxford University-developed coronavirus vaccine shot is 70% effective, compared with success rates of above 90% of those of US rivals Pfizer and Moderna.  The pharma firm's stock was the worst-performing healthcare stock in Europe in early trading.

AstraZeneca slides after announcing its COVID-19 vaccine candidate is 70% effective

Trials showed that the experimental vaccine was 90% effective if administered at a half dose and then at a full dose one month later.

AstraZeneca, Oxford Covid-19 vaccine can be up to 90% effective, late-stage trials show

AstraZeneca Plc (NYSE: AZN) and Oxford University's COVID-19 vaccine prevented 70% of the inoculated trial participants from developing COVID-19, early analysis of trial data indicates, Bloomberg reported Monday. What Happened: The results were based on data gathered from two different dosing regimens.

AstraZeneca COVID-19 Vaccine Shows Up To 90% Efficacy In Advanced Trials

Johnson & Johnson

Novavax

Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates expressed optimism on the efficacy of COVID-19 vaccines made by various drugmakers in an interview with CNN on Sunday. What Happened: The billionaire told CNN's Fareed Zakaria that while vaccines from Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) have already shown effectiveness against COVID-19 in early data, he expects similar results from AstraZeneca Plc (NYSE: AZN), Johnson & Johnson (NYSE: JNJ) and Novavax, Inc (NASDAQ: NVAX) vaccines.

Bill Gates Says AstraZeneca, Johnson & Johnson, Novavax COVID-19 Vaccines All Likely To Prove 'Very Efficacious And Safe' By February

The COVID-19 vaccine developed by AstraZeneca and The University of Oxford is 70% effective, according to large-scale trial results reported by the BBC on Monday. Researchers said the large-scale trial of more than 20,000 volunteers showed the vaccine stopped people from developing symptoms about 70% of the time.

AstraZeneca and Oxford University announced a 3rd working COVID-19 vaccine, which they say is 70% effective

British pharmaceutical giant AstraZeneca on Monday said an interim analysis of clinical trials showed its coronavirus vaccine has an average efficacy of 70% in protecting against the virus.

Oxford-AstraZeneca Covid vaccine is 70% effective, trial shows

AstraZeneca said its COVID-19 vaccine candidate met its primary endpoint showing protection from COVID-19 occurring 14 days or more after receiving two doses of the vaccine. One dosing regimen showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen showed 62% efficacy when given as two full doses at least one month apart.

AstraZeneca study finds its COVID-19 vaccine effective, with one regimen showing 90% efficacy

Here are ideas for both conservative and aggressive investors.

News for AstraZeneca Stock (AZN)